Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
53 verified discoveries match your filters.
In the randomized, double-blind, placebo-controlled INAVO120 trial, adding inavolisib to palbociclib and fulvestrant significantly delayed disease progression compared with palbociclib and fulvestrant alone, in a PIK3CA-mutated, endocrine-resistant, first-line metastatic breast…
Primary source cited
Last reviewed
In the randomized, double-blind, placebo-controlled INDIGO trial, vorasidenib significantly delayed disease progression (by blinded independent review) and delayed the time to the next anticancer intervention, compared with placebo, in a…
Primary source cited
Last reviewed
Afamitresgene autoleucel is an engineered T-cell therapy — reportedly the first engineered cell therapy approved for a solid tumor in the United States — that received accelerated approval based on…
Primary source cited
Last reviewed